长链非编码RNA与肝细胞癌索拉非尼耐药:分子机制与治疗靶点新进展  

lncRNA and sorafenib resistance of hepatocellular carcinoma:New advances in molecular mechanisms and therapeutic targets

作　　者：陈大红 李琴[1] CHEN Dahong;LI Qin(Department of Clinical Pharmacy,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai200080,China)

机构地区：[1]上海交通大学医学院附属第一人民医院临床药学科,上海200080

出　　处：《现代肿瘤医学》2023年第24期4633-4639,共7页Journal of Modern Oncology

基　　金：上海申康医院发展中心临床三年行动计划(编号:SHDC2020CR4076)。

摘　　要：肝细胞癌(HCC)是一种发病率及死亡率较高的恶性肿瘤,以索拉非尼为代表的全身性药物治疗效果并不理想,索拉非尼耐药严重阻碍其临床应用。近年来不断有报道指出长链非编码RNA(lncRNA)参与调控HCC细胞增殖、凋亡、自噬、转移等生物学过程,诱导索拉非尼耐药。笔者以索拉非尼耐药机制为基点,综述多种与HCC索拉非尼耐药有关的lncRNA,揭示lncRNA通过调控癌细胞增殖与死亡、增强癌细胞恶性特征、促进药物外排的方式诱导HCC索拉非尼耐药,旨在为逆转索拉非尼耐药提供新的治疗思路和潜在靶点,增强HCC患者治疗有效性。Hepatocellular carcinoma(HCC)is a malignant tumor with high morbidity and mortality.The effect of systemic drug treatment represented by sorafenib is not ideal,and its resistance severely hinders effectiveness.In recent years,there are increasing researches point that long non-coding RNA(lncRNA)is involved in the regulation of cell proliferation,apoptosis,autophagy,metastasis and other biological processes in HCC,inducing sorafenib chemoresistance.This article reviews multiple lncRNAs which are related with sorafenib resistance in HCC,suggesting that lncRNA induces sorafenib resistance by regulating cell proliferation and death,enhancing cell malignant characteristics,and promoting drug efflux.This review aims to provide new treatment ideas and potential therapeutic targets for reversing sorafenib resistance,and enhancing the effectiveness of treatment for patients with HCC.

关 键 词：长链非编码RNA 肝细胞癌 耐药 索拉非尼 

分 类 号：R735.7[医药卫生—肿瘤]